Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
REDWOOD CITY, Calif., April 06, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2016 the compensation committee of the company’s board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company’s common stock with a per share exercise price of $13.30, the closing trading price on the grant date, and 3,725 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
